Thymalfasin Research
Thymosin α1 improves outcomes of patients with hepatitis B virus-related acute-on-chronic liver failure
Immunopharmacol Immunotoxicol·April 1, 2026
Zhi-Hui Li, Li-Li Wu, Yuan-Qiang Zhu, Zhao-Xia Hu, Shi-Bo Meng, Zi-Ying Lei, Hui-Juan Cao, Jia-Lei Wang, Jun-Feng Chen, Jing Zhang, Bing-Liang Lin
Summary
Tα1 treatment significantly increased 90-day transplant-free survival by restoring immune balance, reducing regulatory T cell frequencies while preserving early immune activation.
Study Details
Study Design
Open-label randomized controlled trial
Indication
Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF)
Intervention
Standard medical therapy (SMT) vs SMT plus Thymosin α1
Species
Human
Sample Size
73 subjects